Optiscan CEO Dr. Camile Farah recently conducted a webinar with Sharewise where he provided a comprehensive update on our strategic growth initiatives and the exciting innovations driving Optiscan’s future.
Key Highlights Include:
- Expansion into the US Market: We have established a commercial hub in Minnesota, reinforcing our commitment to advancing digital pathology and precision surgery in the world’s largest healthcare market.
- Innovative Imaging Technology: Our patent-protected miniaturized confocal microscopy device brings high-resolution, real-time digital pathology imaging directly into the hands of surgeons, reducing the need for traditional biopsies and improving surgical outcomes.
- Robust Pipeline of Clinical Applications: We are focused on cancer diagnosis and treatment, with major progress in breast cancer surgery and head, neck, and GI cancer imaging.
- Partnership with Mayo Clinic: Our strategic collaboration with the Mayo Clinic will drive further innovations in robotic-assisted surgery.
- AI and Telepathology: We are building AI algorithms for diagnostics in oral, breast, and GI cancers, and expanding into intraoperative telepathology, enabling doctors to receive real-time remote pathology insights, driving efficiency and accuracy.
As Dr. Camile Farah emphasised during the webinar:
"Our technology is bringing unprecedented precision to surgery and pathology, helping doctors make real-time decisions that directly improve patient outcomes. By putting powerful imaging tools in the hands of surgeons, we are transforming healthcare for the better—minimizing invasive procedures, reducing repeat surgeries, and enabling personalized treatment plans."
Watch the full webinar recording below:
